Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-20T07:16:27.828Z Has data issue: false hasContentIssue false
  • English
  • Français

Orphan Tests

Published online by Cambridge University Press:  29 July 2009

Leslie G. Biesecker
Leslie G. Biesecker
Affiliation:
A pediatric geneticist in the Laboratory of Genetic Disease Research at the National Center for Human Genome Research, National Institutes of Health.
Get access Rights & Permissions [Opens in a new window]

Extract

An urgent need for standards and guidelines on genetic testing has arisen because of swift advances in research, facilitated by the Human Genome Project. The goals of the Human Genome Project include the identification of all genes and sequencing of the human genome. The project is currently ahead of schedule and under budget. We can expect an avalanche of genetic information, much of which will be relevant to human disease. In addition to the Human Genome Project, investigator-initiated research projects and commercial biotechnology laboratories are discovering human disease genes at a breathtaking pace. Technology transfer has been rapid and has led to the availability of numerous clinical tests within only a few years since the first disease gene yielded to the technique of positional cloning. Disease genes are selected for study for a number of reasons. Genes for rare diseases may be studied before more common disorders because they elucidate an important area of pathogenesis. Unfortunately, technology transfer to the clinic for rare tests is hindered by several factors. Standards need to be established to assure that genetic tests for rare diseases are not ignored or mismanaged in the rush to commercialize tests for more common human genetic diseases.

Type
Genethics
Information
Cambridge Quarterly of Healthcare Ethics , Volume 5 , Issue 2 , Spring 1996 , pp. 300 - 306
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Notes

1. Collins, FS, Galas, D. A new five year plan for the U.S. Human Genome Project. Science 1993;262:43–6.CrossRefGoogle ScholarPubMed

2. Koshland, DE Jr. Ahead of schedule and on budget. Science 1994;266:199.CrossRefGoogle ScholarPubMed

3. Mansfield, B, Ed. Genome centers provide overview and genetic map goal met ahead of schedule. Human Genome News 1994;6:1–14.Google Scholar

4. Collins, FS. Positional cloning moves from perditional to traditional. Natural Genetics 1995;9:347–50.CrossRefGoogle ScholarPubMed

5. Thoene, JG. Current status of orphan disease drug development. Current Opinions in Pediatrics 1994;6:209–12.CrossRefGoogle ScholarPubMed

6. Motulsky, AG. Frequency of sickling disorders in U.S. blacks. New England Journal of Medicine 1973;288:31.CrossRefGoogle ScholarPubMed

7. Welsh, MJ, Tsui, L-C, Boat, TF, Beaudet, AL. Cystic fibrosis. In: Scriver, CR, Beaudet, AL, Sly, WS, Valle, D, Eds. The Metabolic and Molecular Basis of Inherited Disease, Vol 3. New York: McGraw-Hill, 1995:3848.Google Scholar

8. Biesecker, LG, Graham, JM Jr. Syndrome of the month: Pallister-Hall syndrome. Journal of Medical Genetics [Submittedrsqb;.Google Scholar

9. Beaudet, AL. Aspartoacylase deficiency (Canavan disease). In: Scriver, CR, Beaudet, AL, Sly, WS, Valle, D, Eds. The Metabolic and Molecular Basis of Inherited Disease, Vol 3. New York: McGraw-Hill, 1995:4599–605.Google Scholar

10. Andrews, LB, Fullarton, JE, Holtzman, NA, Motulsky, AG. Laboratory issues in human genetics. In: Andrews, LB, Fullarton, JE, Holtzman, NA, Motulsky, AG, Eds. Assessing Genetic Risk: Implications for Health and Social Policy. Washington, DC: National Academy Press, 1994:116–45.Google Scholar

11. Biesecker, LG. Commentary. Cambridge Quarterly of Healthcare Ethics 1995;4:389–92.Google Scholar

12. See note 5. Thoene, . 1994;6:209–12.Google Scholar

13. Asbury, CH. Evolution and current status of the Orphan Drug Act. International Journal of Technological Assessment of Health Care 1992;8:573–82.CrossRefGoogle Scholar

14. Coster, JM. Recombinant erythropoietin. Orphan product with a silver spoon. International Journal of Technological Assessment of Health Care 1992;8:635–46.CrossRefGoogle Scholar

15. See note 5. Thoene. 1994;6:209-12.Google Scholar

16. MacKay, CR. Developing a test to detect carriers of Huntington's disease. IRB A Review of Human Subjects Research 1984;6:1–5.Google Scholar

17. See note 10. Andrews, et al. 1994:116–45.Google Scholar

18. Federal Register. Federal Register 57(60491). 1992.

19. Federal Register. Federal Register 57(40). 1992.

20. See note 10. Andrews, et al. 1994 :116–45.Google Scholar

21. Popovich, B. Private communication. 1995.Google Scholar